Literature DB >> 20837465

Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by sequestosome 1 and histone deacetylase 6.

Takeshi Into1, Megumi Inomata, Shumpei Niida, Yukitaka Murakami, Ken-ichiro Shibata.   

Abstract

MyD88 is an essential adaptor molecule for Toll-like receptors (TLRs) and interleukin (IL)-1 receptor. MyD88 is thought to be present as condensed forms or aggregated structures in the cytoplasm, although the reason has not yet been clear. Here, we show that endogenous MyD88 is present as small speckle-like condensed structures, formation of which depends on MyD88 dimerization. In addition, formation of large aggregated structures is related to cytoplasmic accumulation of sequestosome 1 (SQSTM1; also known as p62) and histone deacetylase 6 (HDAC6), which are involved in accumulation of polyubiquitinated proteins. A gene knockdown study revealed that SQSTM1 and HDAC6 were required for MyD88 aggregation and exhibited a suppressive effect on TLR ligand-induced expression of IL-6 and NOS2 in RAW264.7 cells. SQSTM1 and HDAC6 were partially involved in suppression of several TLR4-mediated signaling events, including activation of p38 and JNK, but they hardly affected degradation of IκBα (inhibitor of nuclear factor κB). Biochemical induction of MyD88 oligomerization induced recruitment of SQSTM1 and HDAC6 to the MyD88-TRAF6 signaling complex. Repression of SQSTM1 and HDAC6 enhanced formation of the MyD88-TRAF6 complex and conversely decreased interaction of the ubiquitin-specific negative regulator CYLD with the complex. Furthermore, ubiquitin-binding regions on SQSTM1 and HDAC6 were essential for MyD88 aggregation but were not required for interaction with the MyD88 complex. Thus, our study reveals not only that SQSTM1 and HDAC6 are important determinants of aggregated localization of MyD88 but also that MyD88 activates a machinery of polyubiquitinated protein accumulation that has a modulatory effect on MyD88-dependent signal transduction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837465      PMCID: PMC2975200          DOI: 10.1074/jbc.M110.126904

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon.

Authors:  Chen Wang; Taoyong Chen; Jia Zhang; Mingjin Yang; Nan Li; Xiongfei Xu; Xuetao Cao
Journal:  Nat Immunol       Date:  2009-05-31       Impact factor: 25.606

2.  A role for NBR1 in autophagosomal degradation of ubiquitinated substrates.

Authors:  Vladimir Kirkin; Trond Lamark; Yu-Shin Sou; Geir Bjørkøy; Jennifer L Nunn; Jack-Ansgar Bruun; Elena Shvets; David G McEwan; Terje H Clausen; Philipp Wild; Ivana Bilusic; Jean-Philippe Theurillat; Aud Øvervatn; Tetsuro Ishii; Zvulun Elazar; Masaaki Komatsu; Ivan Dikic; Terje Johansen
Journal:  Mol Cell       Date:  2009-02-27       Impact factor: 17.970

3.  The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway.

Authors:  L Sanz; M T Diaz-Meco; H Nakano; J Moscat
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

4.  Nucleoredoxin negatively regulates Toll-like receptor 4 signaling via recruitment of flightless-I to myeloid differentiation primary response gene (88).

Authors:  Tatsuya Hayashi; Yosuke Funato; Takeshi Terabayashi; Akifumi Morinaka; Reiko Sakamoto; Hirotake Ichise; Hiroyuki Fukuda; Nobuaki Yoshida; Hiroaki Miki
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

5.  TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation.

Authors:  Mude Shi; Weiwen Deng; Enguang Bi; Kairui Mao; Yongyong Ji; Guomei Lin; Xiaodong Wu; Zhiyun Tao; Zhenhu Li; Xinfen Cai; Shuhui Sun; Charlie Xiang; Bing Sun
Journal:  Nat Immunol       Date:  2008-03-16       Impact factor: 25.606

6.  Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.

Authors:  Su-Chang Lin; Yu-Chih Lo; Hao Wu
Journal:  Nature       Date:  2010-05-19       Impact factor: 49.962

Review 7.  A role for ubiquitin in selective autophagy.

Authors:  Vladimir Kirkin; David G McEwan; Ivana Novak; Ivan Dikic
Journal:  Mol Cell       Date:  2009-05-15       Impact factor: 17.970

8.  Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival.

Authors:  Octavia M Peck-Palmer; Jacqueline Unsinger; Katherine C Chang; Christopher G Davis; Jonathan E McDunn; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2008-01-22       Impact factor: 4.962

9.  The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity.

Authors:  Ji Young Kim; Keiko Ozato
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 10.  p62 at the crossroads of autophagy, apoptosis, and cancer.

Authors:  Jorge Moscat; Maria T Diaz-Meco
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

View more
  34 in total

1.  Autophagy suppresses interleukin-1β (IL-1β) signaling by activation of p62 degradation via lysosomal and proteasomal pathways.

Authors:  Jongdae Lee; Hye Ri Kim; Christine Quinley; Joanna Kim; Jose Gonzalez-Navajas; Ramnik Xavier; Eyal Raz
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 2.  Selective autophagy mediated by autophagic adapter proteins.

Authors:  Terje Johansen; Trond Lamark
Journal:  Autophagy       Date:  2011-03       Impact factor: 16.016

3.  Structural basis of TIR-domain-assembly formation in MAL- and MyD88-dependent TLR4 signaling.

Authors:  Thomas Ve; Parimala R Vajjhala; Andrew Hedger; Tristan Croll; Frank DiMaio; Shane Horsefield; Xiong Yu; Peter Lavrencic; Zahid Hassan; Garry P Morgan; Ashley Mansell; Mehdi Mobli; Ailis O'Carroll; Brieuc Chauvin; Yann Gambin; Emma Sierecki; Michael J Landsberg; Katryn J Stacey; Edward H Egelman; Bostjan Kobe
Journal:  Nat Struct Mol Biol       Date:  2017-07-31       Impact factor: 15.369

4.  A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy.

Authors:  John R North; Shunsuke Takenaka; Annett Rozek; Agnieszka Kielczewska; Steven Opal; Lisa A Morici; B Brett Finlay; Christopher J Schaber; Richard Straube; Oreola Donini
Journal:  J Biotechnol       Date:  2016-03-23       Impact factor: 3.307

Review 5.  HDAC inhibitor-based therapies: can we interpret the code?

Authors:  Maria New; Heidi Olzscha; Nicholas B La Thangue
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

6.  The Brucella TIR-like protein TcpB interacts with the death domain of MyD88.

Authors:  Anu Chaudhary; Kumkum Ganguly; Stéphanie Cabantous; Geoffrey S Waldo; Sofiya N Micheva-Viteva; Kamalika Nag; William S Hlavacek; Chang-Shung Tung
Journal:  Biochem Biophys Res Commun       Date:  2011-11-29       Impact factor: 3.575

7.  Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Authors:  Charles A Dinarello; Gianluca Fossati; Paolo Mascagni
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

8.  MyD88 interacts with interferon regulatory factor (IRF) 3 and IRF7 in Atlantic salmon (Salmo salar): transgenic SsMyD88 modulates the IRF-induced type I interferon response and accumulates in aggresomes.

Authors:  Dimitar B Iliev; Mehrdad Sobhkhez; Kjersti Fremmerlid; Jorunn B Jørgensen
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

9.  HDAC6 regulates mutant SOD1 aggregation through two SMIR motifs and tubulin acetylation.

Authors:  Jozsef Gal; Jing Chen; Kelly R Barnett; Liuqing Yang; Erin Brumley; Haining Zhu
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

10.  Effects of aerobic training on markers of autophagy in the elderly.

Authors:  Yubisay Mejías-Peña; Paula Rodriguez-Miguelez; Rodrigo Fernandez-Gonzalo; Susana Martínez-Flórez; Mar Almar; José A de Paz; María J Cuevas; Javier González-Gallego
Journal:  Age (Dordr)       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.